Connect Biopharma Holdings Limited
CNTB
$2.12
-$0.08-3.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -275.46% | -255.00% | -118.64% | -76.44% | 69.03% |
| Total Depreciation and Amortization | 3.89% | 6.67% | 11.91% | 25.79% | 6.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.56% | -56.32% | -44.62% | -19.80% | 36.27% |
| Change in Net Operating Assets | 114.06% | 103.74% | 117.84% | 122.06% | -230.07% |
| Cash from Operations | -73.60% | -116.86% | -42.89% | -52.28% | -0.69% |
| Capital Expenditure | 57.52% | 42.13% | -119.52% | -929.27% | -1,408.66% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | 100.00% | 0.00% | 0.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 213.22% | 479.49% | -148.96% | -157.23% | -148.44% |
| Cash from Investing | 209.35% | 384.50% | -151.68% | -158.90% | -149.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8,071.62% | 381.50% | 265.28% | 86.81% | 573.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8,071.62% | 381.50% | 136.67% | -6.60% | 116.04% |
| Foreign Exchange rate Adjustments | 235.45% | 168.57% | -398.10% | 62.74% | 56.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.48% | -45.41% | -1,754.27% | -344.61% | -296.11% |